Assembly eliminates Medicaid prior authorization for antiretroviral drugs

The Assembly passed legislation to prohibit Medicaid plans from requiring prior authorization for certain antiretroviral prescription drugs used to treat or prevent HIV and AIDS.

Sponsor explanation

Sponsor Miss Rosenthal said the bill "would ensure that Medicaid providers are not required to obtain prior authorization to prescribe antiretroviral prescription drugs for the treatment or prevention of HIV AIDS." She cited American Medical Association research showing prior authorization delays can cause patients to abandon treatment or experience treatment delays.

Debate and concerns

Members expressed support for increasing access to pre‑exposure prophylaxis (PrEP), post‑exposure prophylaxis (PEP) and other antiretrovirals while some members noted concerns about balancing patient access and plan oversight. "I am supportive of this bill and will be casting a yay vote for it," Assembly member Jensen said but added a note of caution on managing Medicaid spending and clinical oversight.

Vote and outcome

The Assembly recorded the vote as Ayes 142; Noes 0. The bill passed unanimously with recorded voice vote in the transcript.

Implementation

The bill extends to Medicaid the prior policies already enacted for many private plans and intends to reduce delays in access to life‑saving antiretroviral medications, sponsors said. It will require affected Medicaid managed‑care plans not to impose prior authorization for the specified drugs, and agencies will update plan requirements accordingly.

Ending note

Supporters framed the change as closing a gap in access for Medicaid beneficiaries and promoting public‑health prevention and treatment.